Abstract: Provided is an orally administrable vaccine against a coronavirus infectious disease. A transformed Bifidobacterium designed to display a part or a whole of a constituent protein of a coronavirus on a surface of the Bifidobacterium enables the provision of the orally administrable vaccine against a coronavirus infectious disease. The transformed Bifidobacterium designed to display a part or a whole of a constituent protein of a coronavirus on a surface of the Bifidobacterium can induce humoral immunity and cellular immunity through oral administration to suppress an increase in severity of pneumonia or the like even after viral infection.

Abstract: A culture system for co-culturing a first cell group consisting of one or more kinds of cells and a cell layer or tissue formed of a second cell group consisting of one or more kinds of cells different from the former cells comprising: a first culture tank for co-culturing under anaerobic conditions the first cell group consisting of one or more kinds of cells and the cell layer or tissue formed of the second cell group consisting of one or more kinds of cells; a second culture tank for pooling a liquid culture medium of aerobic conditions; one or more substance-exchange structures that are disposed so as to connect the first culture tank to the second culture tank; and the aforesaid cell layer or tissue that is disposed so as to cover the surface on the first culture tank side of the substance-exchange structure(s).

Abstract: A cancer vaccine that can be orally administered can be provided through the use of a transformed Bifidobacterium capable of expressing and displaying a WT1 protein. The WT1 protein expressed and displayed by the transformed Bifidobacterium is a protein covering most of a WT1 protein unlike a WT1 peptide vaccine restricted to a certain HLA. A cancer vaccine using the transformed Bifidobacterium as an active ingredient is applicable to patients of various HLA types.

Abstract: A culture system for co-culturing a first cell group consisting of one or more kinds of cells and a cell layer or tissue formed of a second cell group consisting of one or more kinds of cells different from the former cells comprising: a first culture tank for co-culturing under anaerobic conditions the first cell group consisting of one or more kinds of cells and the cell layer or tissue formed of the second cell group consisting of one or more kinds of cells; a second culture tank for pooling a liquid culture medium of aerobic conditions; one or more substance-exchange structures that are disposed so as to connect the first culture tank to the second culture tank; and the aforesaid cell layer or tissue that is disposed so as to cover the surface on the first culture tank side of the substance-exchange structure(s).

Abstract: A cancer vaccine that can be orally administered can be provided through the use of a transformed Bifidobacterium capable of expressing and displaying a WT1 protein. The WT1 protein expressed and displayed by the transformed Bifidobacterium is a protein covering most of a WT1 protein unlike a WT1 peptide vaccine restricted to a certain HLA. A cancer vaccine using the transformed Bifidobacterium as an active ingredient is applicable to patients of various HLA types.

Abstract: Provided is a gene for expressing an immunogenic polypeptide on the cell surface of a bifidobacterium, and the gene includes a gene encoding the immunogenic polypeptide, the immunogenic polypeptide includes a predetermined base domain and at least one antigenic peptide, and the at least one antigenic peptide is linked on any of the N-terminal side and the C-terminal side of the base domain. The gene for expressing an immunogenic polypeptide on a cell surface of a bifidobacterium of the present invention can further include a gene encoding a bifidobacterium-derived GNB/LNB substrate-binding membrane protein.

Abstract: Provided is a gene for expressing an immunogenic polypeptide on the cell surface of a bifidobacterium, and the gene includes a gene encoding the immunogenic polypeptide, the immunogenic polypeptide includes a predetermined base domain and at least one antigenic peptide, and the at least one antigenic peptide is linked on any of the N-terminal side and the C-terminal side of the base domain. The gene for expressing an immunogenic polypeptide on a cell surface of a bifidobacterium of the present invention can further include a gene encoding a bifidobacterium-derived GNB/LNB substrate-binding membrane protein.

Abstract: According to the present invention, there is provided a means of expressing and displaying a protein on the cell surface of a bifidobacterium. In the gene for expressing a protein on the surface of a bifidobacterium of the present invention, a gene coding for a bifidobacterium-derived GNB/LNB substrate-binding membrane protein and a gene coding for the target protein or peptide are linked in this order from the 5? end side. Thus, a bifidobacterium transformed by introducing the gene for expressing a protein on the surface of a bifidobacterium of the present invention expresses the target protein or peptide on the surface thereof. When the target protein or peptide is an antigen protein or an antigen peptide, the transformed bifidobacterium of the present invention is useful as an oral vaccine.

Abstract: According to the present invention, there is provided a means of expressing and displaying a protein on the cell surface of a bifidobacterium. In the gene for expressing a protein on the surface of a bifidobacterium of the present invention, a gene coding for a bifidobacterium-derived GNB/LNB substrate-binding membrane protein and a gene coding for the target protein or peptide are linked in this order from the 5? end side. Thus, a bifidobacterium transformed by introducing the gene for expressing a protein on the surface of a bifidobacterium of the present invention expresses the target protein or peptide on the surface thereof. When the target protein or peptide is an antigen protein or an antigen peptide, the transformed bifidobacterium of the present invention is useful as an oral vaccine.

Abstract: A mutant tyrosine repressor that does not require tyrosine to induce expression of tyrosine phenol-lyase gene is obtained by introducing a mutation into a tyrosine repressor. A microorganism which is able to express large amounts of tyrosine phenol-lyase is obtained by introducing the mutant tyrosine repressor into the microorganism. The microorganism is useful for producing L-DOPA.

Abstract: A mutant tyrosine repressor that does not require tyrosine to induce expression of tyrosine phenol-lyase gene is obtained by introducing a mutation into a tyrosine repressor. A microorganism which is able to express large amounts of tyrosine phenol-lyase is obtained by introducing the mutant tyrosine repressor into the microorganism. The microorganism is useful for producing L-DOPA.

Abstract: The present invention provides a transglycosylation method and a protein catalyzing a transglycosylation reaction. A reaction of transferring a galactosyl?1?3N-acetylgalactosaminyl group from a sugar donor containing a sugar chain having a galactosyl?1?3N-acetylgalactosaminyl group bound thereto at the ?-position, to a sugar chain acceptor, is carried out in the presence of a protein having an endo-?-N-acetylgalactosaminidase activity and a transglycosylation activity.

Abstract: A mutant tyrosine repressor that does not require tyrosine to induce expression of tyrosine phenol-lyase gene is obtained by introducing a mutation into a tyrosine repressor (tyrR), isolated from Pantoea agglomerans, or a tyrosine repressor (tyrR) which is encoded by SEQ ID NO. 1 and its derivative. A microorganism which is able to express large amounts of tyrosine phenol-lyase is obtained by introducing the mutant tyrosine repressor into the microorganism. The microorganism is useful for producing L-DOPA.

Abstract: The present invention provides a transglycosylation method and a protein catalyzing a transglycosylation reaction. A reaction of transferring a galactosyl?1?3N-acetylgalactosaminyl group from a sugar donor containing a sugar chain having a galactosyl?1?3N-acetylgalactosaminyl group bound thereto at the ?-position, to a sugar chain acceptor, is carried out in the presence of a protein having an endo-?-N-acetylgalactosaminidase activity and a transglycosylation activity.

Abstract: The present invention provides a transglycosylation method and a protein catalyzing a transglycosylation reaction. A reaction of transferring a galactosyl?1?3N-acetylgalactosaminyl group from a sugar donor containing a sugar chain having a galactosyl?1?3N-acetylgalactosaminyl group bound thereto at the ?-position, to a sugar chain acceptor, is carried out in the presence of a protein having an endo-?-N-acetylgalactosaminidase activity and a transglycosylation activity.

Abstract: A mutant tyrosine repressor that does not require tyrosine to induce expression of tyrosine phenol-lyase gene is obtained by introducing a mutation into a tyrosine repressor. A microorganism which is able to express large amounts of tyrosine phenol-lyase is obtained by introducing the mutant tyrosine repressor into the microorganism. The microorganism is useful for producing L-DOPA.

Abstract: A gene coding for a mutant tyrosine repressor having increased positive regulatory activity for expression of the tyrosine phenol lyase gene compared with a tyrosine repressor not having mutation is obtained by introducing a mutation into a tyrosine repressor gene of Erwinia herbicola, introducing the gene into which the mutation is introduced into Escherichia coli expressing a lactose operon under the control of a promoter and enhancer of the tyrosine phenol lyase gene derived from Erwinia herbicola, and selecting a transformed strain having increased ?-galactosidase activity.

Abstract: A gene coding for a mutant tyrosine repressor having increased positive regulatory activity for expression of the tyrosine phenol lyase gene compared with a tyrosine repressor not having mutation is obtained by introducing a mutation into a tyrosine repressor gene of Erwinia herbicola, introducing the gene into which the mutation is introduced into Escherichia coli expressing a lactose operon under the control of a promoter and enhancer of the tyrosine phenol lyase gene derived from Erwinia herbicola, and selecting a transformed strain having increased ?-galactosidase activity.

Abstract: A gene coding for a mutant tyrosine repressor having increased positive regulatory activity for expression of the tyrosine phenol lyase gene compared with a tyrosine repressor not having mutation is obtained by introducing a mutation into a tyrosine repressor gene of Erwinia herbicola, introducing the gene into which the mutation is introduced into Escherichia coli expressing a lactose operon under the control of a promoter and enhancer of the tyrosine phenol lyase gene derived from Erwinia herbicola, and selecting a transformed strain having increased &bgr;-galactosidase activity.

Abstract: Using as a host Escherichia coli which expresses lactose operon under the control of the promoter/enhancer of tyrosine phenol lyase gene derived from Erwinia herbicola, a DNA fragment coding for tyrosine repressor (tyrR) having an amino acid sequence depicted in SEQ ID NO: 2 in Sequence Listing is obtained from the chromosome gene library of Erwinia herbicola.